FDA Adds Warning to Veozah Menopause Drug

Regulators said that the drug could lead to serious liver injury, with symptoms including fatigue, nausea, jaundice, dark urine, and abdominal pain.

The U.S. Food and Drug Administration building in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

The U.S. Food and Drug Administration (FDA) said on Sept. 12 that it is adding a warning to Veozah, a drug used to treat hot flashes experienced because of menopause.

Veozah, also known as fezolinetant, “can cause rare but serious liver injury,” the FDA said in an alert.